Jodas Expoim Pvt. Ltd. Company Profile

Background

Founded in 2006, Jodas Expoim Pvt. Ltd. is a global, specialty, innovation-driven pharmaceutical company headquartered in Hyderabad, India. The company is dedicated to providing high-quality, effective, and affordable generic formulations, with a mission to make life-saving medicines accessible to millions worldwide. Jodas focuses on four key therapeutic segments:

• Anti-Infectives (Injectables)

• Anti-Cancer (Injectables & Orals)

• Contrast Media (Injectables)

• Critical Care (Injectables)

With a presence in over 40 countries, Jodas has established itself as a significant player in the pharmaceutical industry, emphasizing quality and affordability in its product offerings.

Key Strategic Focus

Jodas Expoim's strategic focus centers on the development and commercialization of specialty generic formulations across its four primary therapeutic areas. The company leverages state-of-the-art manufacturing facilities and a robust research and development (R&D) infrastructure to deliver high-quality products. Key objectives include:

• Expansion into Emerging Markets: Strengthening its footprint in emerging markets by offering affordable and effective medications.

• Product Portfolio Diversification: Continuously evolving its product range to include niche and technologically challenging formulations.

• Regulatory Compliance: Maintaining approvals from multiple regulatory bodies, including the EU, Russia, PIC/S, UAE, and SFDA, to ensure global standards of quality and safety.

Financials and Funding

As of March 2024, Jodas Expoim reported total revenue in the range of ₹500-750 crore. The company's authorized share capital stands at ₹115.5 crore, with a paid-up capital of ₹113.2 crore. Key financial metrics include:

• EBITDA: Data not publicly disclosed.

• Net Profit: Data not publicly disclosed.

• Net Worth: Data not publicly disclosed.

• Borrowings: Data not publicly disclosed.

These figures reflect the company's financial stability and capacity for sustained growth.

Pipeline Development

Jodas Expoim has a robust pipeline focusing on the development of biosimilars and complex injectables. Notable developments include:

• Biosimilars: Initiation of projects for biosimilar drugs such as Pertuzumab and Pembrolizumab, with clinical trials and bioequivalence studies conducted across various countries.

• Product Registrations: Over 250 molecule registrations worldwide, with more than 200 molecules under registration, indicating a strong commitment to expanding its product portfolio.

Technological Platform and Innovation

Jodas Expoim distinguishes itself through its advanced technological platforms and commitment to innovation:

• Manufacturing Facilities: State-of-the-art, EU-GMP-certified facilities located in Genome Valley, Hyderabad, encompassing multiple specialized units, including Oncology, Cephalosporin, Contrast Media, and R&D blocks.

• Research and Development: A dedicated R&D center focusing on developing complex formulations and biosimilars, utilizing sophisticated analytical and microbiology labs.

• Proprietary Technologies: Development of user-friendly drug delivery systems such as prefilled syringes, lyophilized powders, and advanced injectors to enhance patient compliance and safety.

Leadership Team

Jodas Expoim's leadership comprises experienced professionals with diverse backgrounds:

• Dr. Jyoti Loomba, Chief Managing Director: A cardiologist with extensive experience in the pharmaceutical industry, particularly in Russia and CIS regions.

• Mr. Shashi Shanker Parsad Singh, Managing Director: A postgraduate in Mechanical Engineering with vast experience in pharmaceutical sales and marketing in Russia.

• Mr. Satyendra Kumar Singh, Managing Director: A postgraduate in Automation Engineering, responsible for R&D and new facility development.

The core team also includes:

• Mr. Piyush Gupta, Vice President – Operations & Supply Chain Management

• Mr. Anand Vijaywargia, Chief Financial Officer

• Mr. Rahul Verma, Director – HR & Admin

• Dr. Prasanna Devarneni, President – Bio-Technology

• Mr. Prashant Kumar Nayak, Sr. Vice President – Operations

• Mr. M A Krishna Kumar, Vice President – CQC

• Mr. K. Umamaheswara Reddy, Principal Scientist – AR&D

• Mr. Obul Reddy, GM – Operations

• Dr. Srikanth Reddy. S, Head – Drug Regulatory Affairs & Clinical

• Dr. Prriya Dubey, Head Pharmacovigilance, Bioequivalence, Clinical Trial and Medical Affairs, Company Brand Ambassador & Chief – CSR

Competitor Profile

Market Insights and Dynamics:

The global pharmaceutical industry is highly competitive, with significant growth potential driven by increasing healthcare needs and the demand for affordable medications. Jodas Expoim operates in a market characterized by rapid innovation and stringent regulatory requirements.

Competitor Analysis:

Key competitors include:

• Hikma Pharmaceuticals: Focuses on a wide range of generic and branded generic pharmaceutical products.

• Sun Pharma: Develops generic prescription products in various dosage forms.

• Torrent Pharmaceuticals: Manufactures a wide range of pharmaceutical products.

• Divis Laboratories: Specializes in developing processes for the production of Active Pharmaceutical Ingredients (APIs) and intermediates.

Strategic Collaborations and Partnerships

Jodas Expoim has engaged in significant collaborations to enhance its market position and innovation capacity:

• Global Expansion: Established a consolidated presence in over 40 countries, with plans to extend manufacturing facilities to Russia and CIS regions.

• Regulatory Approvals: Achieved approvals from nine regulatory bodies, including the EU, Russia, PIC/S, UAE, and SFDA, facilitating entry into diverse markets.

Operational Insights

Jodas Expoim's strategic considerations include:

• Manufacturing Excellence: Operating EU-GMP-certified facilities with multiple specialized units to ensure high-quality production.

• Innovation Focus: Investing in R&D to develop complex formulations and biosimilars, addressing unmet medical needs.

• Market Diversification: Expanding into emerging markets to increase accessibility to affordable medications.

Strategic Opportunities and Future Directions

Jodas Expoim's strategic roadmap includes:

• Biosimilars Development: Advancing biosimilar projects to offer cost-effective alternatives to biologic therapies.

• Facility Expansion: Extending manufacturing capabilities to Russia and CIS regions to meet growing demand.

• Regulatory Compliance: Maintaining and obtaining approvals from additional regulatory bodies to facilitate global market entry.

Contact Information

• Website: jodasexpoim.in

• LinkedIn: linkedin.com/company/jodasexpoim

• Facebook: facebook.com/jodasexpoim

• Instagram: instagram.com/jodasexpoim

Jodas Expoim Pvt. Ltd. continues to assert itself among the world's foremost pharmaceutical companies, driven by a commitment to innovation, quality, and global healthcare accessibility.